Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tipelukast · MN-001, KCA-757

Small molecule · developed by MediciNova

Phase 2 Most advanced trial

MNOV Developer

2 Registered trials

What is Tipelukast?

Tipelukast (MN-001) is an orally bioavailable small molecule compound studied in type 2 diabetes mellitus, hypertriglyceridemia, non-alcoholic fatty liver disease, and interstitial cystitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MN-001, KCA-757
Drug type: Small molecule
Therapy area: Endocrine, Metabolic, Renal & urology
Developer: MediciNova (MNOV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 08379P260O

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05464784	Phase 2	Diabetes Mellitus, Type 2	Active not recruiting	MNOV
NCT00295854	Phase 2	Interstitial Cystitis	Completed	MNOV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 2HypertriglyceridemiaNon-Alcoholic Fatty Liver DiseaseInterstitial Cystitis

More from MediciNova

Bedoradrine Phase 2 Ibudilast Phase 2/3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MNOV page.

Follow MNOV, the company behind Tipelukast

See MNOV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNOV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z